Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D4Q5AW
|
|||
Drug Name |
Beraprost
|
|||
Synonyms |
beraprost; 88430-50-6; 88430-50-6 (free acid); 1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-; Beraprost (USAN); GTPL1967; SCHEMBL1554142; SCHEMBL1554145; BDBM85181; CAS_2352; NSC_2352; 4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid; K578; D02720; L024061; Q5977854; (E)-4-(2-hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-ynyl)-2,3,3a,8b-tetrahydro-1H-benzo[d]cyclopenta[b]furan-5-yl)butanoic acid; 4-(2-Hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran-5-yl)butanoic acid; 4-{4-hydroxy-3-[(1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-7-oxatricyclo[6.4.0.0^{2,6}]dodeca-1(12),8,10-trien-9-yl}butanoic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Pulmonary hypertension [ICD-11: BB01; ICD-10: I27, I27.0; ICD-9: 416] | Phase 4 | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C24H30O5
|
|||
Canonical SMILES |
CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
|
|||
InChI |
1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+
|
|||
InChIKey |
CTPOHARTNNSRSR-OUKQBFOZSA-N
|
|||
CAS Number |
CAS 88430-50-6
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Prostacyclin receptor (PTGIR) | Target Info | Agonist | [2] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Vascular smooth muscle contraction | ||||
Platelet activation | ||||
Pathwhiz Pathway | Intracellular Signalling Through Prostacyclin Receptor and Prostacyclin | |||
Pathway Interaction Database | Thromboxane A2 receptor signaling | |||
Reactome | Prostanoid ligand receptors | |||
G alpha (s) signalling events | ||||
WikiPathways | Prostaglandin Synthesis and Regulation | |||
GPCRs, Class A Rhodopsin-like | ||||
Small Ligand GPCRs | ||||
Endothelin Pathways | ||||
Platelet homeostasis | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03431649) Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children. U.S. National Institutes of Health. | |||
REF 2 | Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.